Introduction {#s0005}
============

Breast cancer (BC) is the most common cancer of women worldwide ([@bb0100]). In Egypt, the disease accounts for 37% of womens cancer with an incidence rate of 49.6/100,000 ([@bb0165]) and it is predicted to be a significant increase in BC caseloads from 2009 to 2015 among women aged 30--49 years ([@bb0155]). It has been estimated that hypercoagulation state accounts for a significant percentage of mortality and morbidity in cancer patients ([@bb0055]). This state has been linked to a chronic low-grade disseminated intravascular coagulopathy (DIC), with vascular thromboembolic events (VTE) occurring both alone and in the presence of DIC ([@bb0075]).

As a potent inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI) has been isolated and characterized from human plasma. This zymogen can be activated by thrombin, plasmin or the thrombin thrombomodulin complex of the carboxypeptidase B-like enzyme, TAFIa (activated TAFI). When exposed to a fibrin clot, TAFIa catalyzes the removal of carboxyl-terminal lysines, thereby diminishing the cofactor activity for plasminogen activation. Less efficient plasminogen activation on the fibrin clot corresponds to prolongation of fibrinolysis, and TAFIa can serve as a potent antifibrinolytic enzyme by this way ([@bb0220]). Non-modifiable factors such as polymorphisms in the genes encoding these proteins that may affect their structure, concentration, or function, might have an influence in the balance between coagulation and fibrinolysis and should be investigated to help identify a subset of patients at higher risk. Several single nucleotide polymorphisms (SNPs) of the *TAFI* gene have been identified ([@bb0045]). This gene is located on chromosome 13q14.11, spanning \~ 48 kb and consisting of 11 exons ([@bb0035]). Plasma TAFI levels or function has been related to these polymorphisms, of which is 1040 C/T SNP as described in the NCBI SNP database (rs1926447) in the coding region that results in the conversion of a Threonine codon (ACU) to an Isolucine codon (AUU) at a position 325 (Thr325Ile) is of particular interest since it has been shown that the presence of an Ile325 residue has a positive influence on both TAFIa activity and stability in vitro resulting in increased antifibrinolytic activity ([@bb0220]). Although several reports have been published on the relationship between TAFI and deep vein thrombosis ([@bb0205]), DIC ([@bb0245]), ischemic stroke ([@bb0090], [@bb0195]), coronary artery disease ([@bb0175], [@bb0230], [@bb0235]), and diabetes mellitus ([@bb0005]), the potential role of TAFI in tumor development remains controversial.

Apparently, any disturbance in TAFI levels or its activity may contribute to increased rates of thrombotic complications in cancer patients ([@bb0060]). To the best of our knowledge, this is the first work on relation between *TAFI* polymorphism and BC in our population (Caucasian ancestry). Here, we investigated the associations of Thr325Ile *TAFI* polymorphism and its plasma level with BC and its progress. In combination with other genetic and non-genetic data, this could be helpful in refining a prognostic profile for cancer patients and identify those who are prone to thromboembolic events.

Subjects and methods {#s0010}
====================

Participants {#s0015}
------------

### Patients {#s0070}

One hundred and fifty newly diagnosed female patients (mean age; 52.1 ± 13.8 years) with pathologically proven BC were recruited between 2011 and 2013 from the Oncology Diagnostic Unit of Suez Canal University Hospital. BC patients were further stratified into two subgroups; those in early stages with no distant metastases (stages I and II; n = 80, mean age 50.1 ± 8.6 years) and a group in late stages of BC with invasive behavior and distant metastases (stages III and IV; n = 70, mean age 52.4 ± 12.5). BC was diagnosed based on the pathological examination and the relevant stage was assigned according to the TNM classification of the Sixth Edition of the American Joint Committee on Cancer (AJCC) Manual for Staging of Cancer ([@bb0225]) and graded by the Nottingham grading system ([@bb0215]). There was no pre-surgical treatment of chemotherapy, radiotherapy, endocrine therapy or biotherapy. All relevant clinical and pathological information was retrieved from their files, including tumor size, type, grade and stage at the time of diagnosis, presence of lymph node metastases, estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) expression in BC tissue. Receptor status was used to divide breast cancer into four biological tumor subtypes; Luminal A, Luminal B (triple positive), Basal-like (triple negative) and HER2^+^ subsets ([@bb0200]). A scoring assessment of prognosis for each patient was performed using both the Nottingham Prognostic Index (NPI) and Immunohistochemical Prognostic Index (IHPI) to predict the overall and disease free survival. The former index is based on 3 prognostic indicators; tumor size, histological grade, and lymph-node status; patients with NPI of ≤ 3.4 have a good prognosis, 3.4 \> NPI ≤ 5.4 is moderate, and of \> 5.4 has a poor prognosis, with 5-year survival rates of 85%, 70%, and 50%, respectively ([@bb0120], [@bb0160]). The IHPI was used as a complementary index to the NPI, based on the three receptor status; ER, PR and HER2. It was calculated as follows: one point will be assigned for each positive value for HER2 and zero points will be given for negative values; one point will be given for any negative value of ER or PR and zero points will be given when positive. Tumors were ranked from 0 to 4 points using the arithmetic sum of the three individual immunohistochemical factors, and grouped into good prognosis (0--1 points), moderate prognosis (2 points), or poor prognosis (3 points) ([@bb0125]). The risk of recurrence of each patient was estimated according to the European Society of Medical Oncology (ESMO) Clinical Recommendations for follow-up of primary breast cancer, and it was classified into three categories; low, intermediate and high risk of recurrence ([@bb0180]). The clinicopathological features of BC patients were presented in [Table 1](#t0005){ref-type="table"}.

### Controls {#s0075}

The control group included 150 unrelated apparently healthy women (mean age 50.2 ± 4.2 years), not suffering from any disease interfering with the study and had no family history of BC or any other neoplastic diseases. They were recruited from blood bank donors.

The study was conducted in accordance with the guidelines in the Declaration of Helsinki and was approved by the Ethical Committee of the Faculty of Medicine, Suez Canal University. An informed consent was obtained from all participants.

Blood sample collection {#s0020}
-----------------------

From patient and control group venous blood samples were collected under a complete aseptic condition on citrate (3.8% trisodium citrate, 0.129 mmol/l), centrifuged at 2500 g for 30 min at 4 °C and platelet-poor plasma was divided into aliquots and kept frozen at − 80 °C until analysis (within 6 months). At the same time when blood samples were taken, whole blood cell count, liver function tests, renal function tests and coagulation parameters were also detected. For genotyping studies, samples were drawn in trisodium EDTA (1 mg/ml) tubes.

Laboratory methods {#s0025}
------------------

Quantification of TAFI Ag level was performed with a commercially available Zymutest TAFI Ag enzyme linked immunosorbent assay (ELISA) kit (Hyphen BioMed, France), which contained a capture antibody (monoclonal antibody specific for human TAFI) and a detecting antibody (polyclonal labeled antibody). The intra and interassay coefficients of variability were 2.8% and 1.9%; respectively. Results were expressed as percentage of normal pooled plasma (NPP) from 30 healthy volunteers from the blood bank.

White blood cell count (WBC) was detected by an automated cell counter (Cell Dyne-2700, Abbott Lab., USA). Liver and renal function tests, including serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), albumin, creatinine, and blood urea nitrogen were routinely determined using CX-9 Beckman (Coulter., France) with the company\'s original kits. The coagulation parameters, including prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and D-dimer (Latex enhanced immune turbidity method) were assayed using CA-1500 system blood coagulation analyzer (Sysmex, Japan).

Genotyping {#s0030}
----------

Genomic DNA was extracted from peripheral blood leukocytes using the Wizard® Genomic DNA Purification Kit (Promega, Madison, Wisconsin, USA), quantified by absorbance at 260 nm using Nanodrop-1000 spectrophotometer (NanoDrop Tech., Wilmington, USA) and stored at − 80 °C. *TAFI* Thr325Ile SNP (rs1926447) was genotyped using a real-time PCR allelic discrimination TaqMan assay (Applied Biosystems, California, USA) on StepOne™ Real-Time PCR System (Applied Biosystems, USA) as described in detail previously ([@bb0175]). Genotyping was performed blinded to case/control status. Ten percent of the randomly selected samples were regenotyped in separate runs to exclude the possibility of false genotype calls with 100% concordance.

Statistical analysis {#s0035}
--------------------

Numerical values were analyzed by Student\'s t-test and ANOVA followed by Newman--Keuls post hoc test for inter-sample comparisons. In the case of non parametric data, Mann--Whitney U or Kruskal--Wallis tests for comparing 2 or \> 2 categories; respectively, were used followed by Tukey multiple comparison test. Comparison of allelic and genotype frequencies between groups and association of polymorphism with quantitative traits were examined for statistical significance using standard Pearson chi-square test (χ^2^) or Fisher\'s exact test when appropriate. The odds ratio (OR) was calculated by means of logistic regression and the confidence interval (CI) was calculated at the 95% level. Data were analyzed by Texasoft WINKS 4.651 software (Texas, USA). Statistical significance was assumed for *P* values less than 0.05. The appropriate sample size and power calculations were carried out using [@bb0210] package version 1.2.4 (University of Southern California, <http://hydra.usc.edu/gxe/>). Calculations showed that the sample size, together with the specified study design, allele frequencies and allowable error rates; can give as high as 80% power and can detect a variant allele frequency of at least 0.05. Consistency of genotype frequencies with Hardy--Weinberg equilibrium was tested on a contingency table of observed and expected genotype frequencies using the Markov simulation-based goodness of fit.

Results {#s0040}
=======

Demographic and clinical characterization of the studied groups {#s0045}
---------------------------------------------------------------

Some demographic and basic laboratory parameters of patients and controls are shown in [Table 2](#t0010){ref-type="table"}. Patients and controls were matched as regards age and BMI. However, as compared with normal subjects, patients had significantly higher plasma fibrinogen levels (2.5 ± 1.2 vs. 3.9 ± 1. 6, respectively; *P* \< *0.001*), D-dimer levels (151.0 ± 81.1 vs. 549.5 ± 101.2, respectively; *P* = *0.007*) and TAFI levels (91.1 ± 19.2 vs. 101.3 ± 24.4, respectively; *P* = *0.004*). No significant difference in TAFI antigen levels was observed in relation to the plasma fibrinogen levels and D-dimer values.

Genotype and allele frequencies among studied groups {#s0050}
----------------------------------------------------

The genotype and allele distributions for the *TAFI* Thr325Ile polymorphism of the study groups were shown in [Table 3](#t0015){ref-type="table"}. The genotype distribution of both studied groups fits the Hardy--Weinberg equilibrium estimated with a χ^2^ test (*P* \> 0.05). The genotypes carrying the high risk allele \[Thr/Ile (CT) and Ile/Ile (TT)\] were significantly more frequent in patients compared to control group (50.0% and 22.0% vs. 42.0% and 13.0%, respectively) and were also associated with developing BC in the studied patients (OR: 2.08; \[95% CI: 1.3--3.5\]; *P* = 0.002, [Table 3](#t0015){ref-type="table"}). BC patients were stratified into those in early stages and those in late stages. When compared with controls, there was statistically significant difference only between early BC group and controls regarding the different *TAFI* Thr325Ile genotypes and alleles frequencies ([Table 3](#t0015){ref-type="table"}). However, there was no statistically significant difference in genotype and allele distribution between early stage and late stage BC patients (*P* \> 0.05).

*TAFI* Thr325Ile genotypes and Ag levels among study groups {#s0055}
-----------------------------------------------------------

*TAFI* Thr325Ile polymorphism was significantly correlated with TAFI antigen levels with the C/C genotype corresponding to the highest and the T/T genotype with the lowest TAFI antigen levels in each group (overall *P* \< 0.001, [Fig. 1](#f0005){ref-type="fig"}). Individuals with TT genotype, in addition, showed a significant decrease in plasma TAFI levels as compared with those having CT genotypes in each studied group.

The relation of *TAFI* Thr325Ile polymorphism and Ag levels to clinicopathological parameters of patient group {#s0060}
--------------------------------------------------------------------------------------------------------------

No significant differences in the genotype distributions were found in the different subgroup analyses (including tumor stage, prognosis and risk of recurrence, etc.) for the *TAFI* Thr325Ile polymorphism ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}). However, Patients presented with advanced tumor stage (III and IV) and poorly differentiated tumor, had significantly higher levels of plasma TAFI Ag (*P* = 0.02 and *P* = 0.01, respectively). Regarding the receptor status, higher TAFI Ag levels were significantly associated with HER2^+^ tumors in comparison with other biological sub-types like luminal A, B and basal-like tumors (*P* = 0.01). Higher levels of *TAFI* Ag were also observed in patients with poor prognosis with 5-year survival rates of 50% (either estimated with NPI or IHPI), and those with higher recurrence risk \> 50% (*P* = 0.04 and *P* \< 0.001, respectively; [Table 4](#t0020){ref-type="table"}).

Discussion {#s0065}
==========

Malignant transformation, the net outcome of oncogene activation and suppressor gene inactivation, also induces the genes which control hemostasis as activation of coagulation confers a selective survival advantage on tumor cells ([@bb0030]).

TAFI is a potent direct modulator of fibrinolysis and indirect regulator of plasmin formation and as such could possibly participate in events leading to tumor development and metastasis ([@bb0040]). The contribution of TAFI polymorphisms to cancer development has not been examined so far.

In the present study, we found that *TAFI* Thr325Ile polymorphism was associated with BC, with the genotypes carrying the T allele \[Thr/Ile (CT) and Ile/Ile (TT)\] occurring more frequently in patients with BC (OR = 2.08, 95% CI 1.3--3.5 for combined genotypes; P = 0.002). When patients stratified into early stage BC and a late one, significant association was more evident with the former subgroup. In the literature, the reasons for an association with early-stage cancer than late-stage one are unknown. However, it is possible that some unknown genetic factors may contribute to these different propensities with BC stages ([@bb0130]). Some of the genes, in addition, show age-specific effects. These can confer relative risks that decrease with age ([@bb0085]). As our late stage BC patients were older than early stage one, this assumption will need further studies to clarify.

This finding was in agreement with [@bb0060] who reported similar results in their Chinese Han patients. Otherwise, up to our knowledge, no data are available on the frequency of this variant in other populations of BC patients. In contrast, [@bb0240], observed lack of association between this polymorphism and their 150 European patients with oral squamous cell carcinoma, but this is not necessarily in contradiction to our results, as the etiology of malignant diseases is multifaceted and differs strongly between different cancers.

Regarding the effect of *TAFI* Thr325Ile polymorphism genotypes on TAFI Ag concentration, it was similar in our cases and controls. It was significantly correlated with TAFI antigen levels with the CC genotype corresponding to the highest and the TT genotype to the lowest TAFI antigen levels. This is in accordance with that plasma TAFI concentration is almost entirely genetically determined ([@bb0145]) with a low contribution of measured environmental factors ([@bb0115]). However, we should mention that great care should be taken with the interpretation and comparison of current reported results as the commercially available ELISA kit used in TAFI estimation is genotype artifact-dependent as shown in [@bb0150]. The measurement of 325Thr is higher than 325Ile genotypes, due to the specificity of monoclonal antibody, but as the results presented here show higher levels related to 325Ile genotype in patients, this finding is very reasonable, and even it can be underestimated.

Breast cancer patients showed a significant increase in their plasma TAFI levels, when compared with the control group; contributing to the fibrinolytic deficiency in these patients and reflecting their thrombotic state ([@bb0060], [@bb0105], [@bb0170]). This finding runs in-line with disease progression, as the fibrin accumulation in the tumor could increase endothelial motility, worsen angiogenesis, and contribute to an increased risk of thrombosis in breast cancer patients ([@bb0050], [@bb0080]). Otherwise, this finding disagreed with [@bb0190], with partial explanation for this discrepancy could be related to difference in study population ethnicity (affect gene-gene and gene-environment interactions) and the methods used to measure plasma TAFI, if we excluded from the first the confounder effect of the very small sample size of this study (27 patients with colon cancer, 37 women with BC and 20 healthy persons).

The D-dimer and fibrinogen levels of the patient group in this study were also statistically significantly higher than that of the control group which likely reflects the biology of the underlying tumor ([@bb0185]). D-dimer assessment constitutes a first attempt to consider a product of fibrin degradation as a specific marker related to the extent of disease in human breast cancer ([@bb0020]). Plasma D-dimer levels have been correlated with an enhanced progression of the disease and a reduced overall survival in metastatic breast cancer ([@bb0080]). Its level reflects the hypercoagulability and the fibrinolytic system activity and was significantly increased with fibrinogen levels in newly diagnosed breast cancer patients compared with controls in many previous studies ([@bb0015], [@bb0250]) and in patients with invasive carcinoma compared with those patients with either benign breast disease or carcinoma-in-situ ([@bb0025]).

The association of higher plasma TAFI levels and plasma TAFI lowering alleles (TT) in BC patients than controls; a finding that is opposite to what might be expected, could be attributed to that TAFIa has no known physiologic inhibitors and consequently, its primary regulatory mechanism involves its intrinsic thermal instability. The rate of TAFI activation and stability of the active form function in maintaining its concentration above the threshold value required to down-regulate fibrinolysis ([@bb0110]). In the case of the Ile-325 variant of *TAFI*, changing the Thr residue which is hydrophilic in nature to a hydrophobic Ile residue may diminish the effect of the favorable entropic change that accompanies the inactivation process contributing to TAFIa stabilization. Activated TAFI--Thr325, in addition, has a normal in vitro half-life of 8 min (at 37 °C), whereas activated TAFI--Ile325 has a half-life of about 16 min and a 60% greater antifibrinolytic activity compared to TAFI--Thr325. Possibly, this increased stability and half-life of TAFIa compensates for the effect of TAFI lowering alleles ([@bb0175]). We should consider also that under physiological conditions, liver cells are the main source of TAFI production and during inflammation TAFI acts as an acute reactant protein. In addition to hepatic cells, adipocytes, endothelial and epithelial cells may also produce and secrete TAFI in vitro. Inflammatory cytokines released by malignant cells, in addition, may stimulate the production and secretion of TAFI from liver or vascular endothelial cells and thus augment its systemic circulation ([@bb0135]).

As the risk of VTE is higher in patients with distant metastases ([@bb0070]) and increases with advancing stages of BC ([@bb0010], [@bb0065]), we evaluated *TAFI* Thr325Ile polymorphism and TAFI level at various stages of BC and correlated with other clinicopathological parameters to clarify their roles in relation to BC. There was lack of association between *TAFI* Thr325Ile polymorphism and all evaluated parameters as tumor type, grade, stage and receptor status of breast tissue (*P* \> 0.05). However, BC patients with advanced state (those who have an advanced tumor stage and poorly differentiated type of cancer), bad prognosis and a higher rate of recurrence showed significantly higher plasma TAFI Ag levels. This could be explained by that excessive host fibrin formation as a result of increasing TAFI levels, favors tumor growth, progression, angiogenesis and hematogenous metastasis ([@bb0095]), and contributes to an increased risk of thrombosis in patients with breast cancer ([@bb0080]). As a selective advantage for cancer cells, fibrin provides a scaffold for anchorage and invasion promoting invasive growth ([@bb0030]).

As a limitation of our study should be considered is that identifying a significant association of genetic variation with diseases as BC may need a larger sample size. Our relatively small sample size has an advantage in the low age of participants as breast cancer risk has also been dependent on age ([@bb0155]) and could have an impact on SNP analysis. The present study, in addition, fulfills most of the criteria of a good genetic association study ([@bb0140]) and the first one relates this polymorphism to BC in our region.

In conclusion, *TAFI* Thr325Ile SNP was associated with BC susceptibility in Egyptian females. The current results supported the relation between this polymorphism and plasma TAFI levels. Moreover, TAFI levels may be closely related to tumor progression and may serve as a predictor of poor prognosis in patients with BC. Many further studies, including follow-up one of our patients and controls on larger cohorts will be required to evaluate the prognosis and outcome related to the studied SNP and its level as well as to examine the efficacy of preventive measures in BC patients with a high TAFI plasma level before any immediate rush to use this information to give individual predictions of prognosis. Future studies, in addition, are necessary to elucidate whether TAFI levels (measured by highly specific genotype artifact-independent assay) could be one of the potential markers of tumor response to treatment.

The following is the supplementary data related to this article.Supplementary Table 1TAFI Thr325Ile polymorphism and clinicopathological parameters of breast cancer patients.
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![Correlation between TAFI antigen plasma levels and different *TAFI* Thr325Ile genotypes among study groups. Box and Whisker plot of the TAFI (thrombin-activatable fibrinolysis inhibitor) Ag levels; expressed as percentage of normal pooled plasma, among control (gray box) and patient (white box) groups. The median and interquartile range (25th--75th percentile), are shown as solid horizontal lines. Comparisons were performed by Kruskal--Wallis test followed by Tukey multiple comparison test for each group. \*, indicates significant difference compared to CC carriers in the same group at *P* \< 0.05. \#, indicates significant difference compared to CT carriers in the same group at *P* \< 0.05.](gr1){#f0005}

###### 

The clinicopathological features of breast cancer patients.

  Patient characteristics              Early stages BC patients (n = 80)   Late stages BC patients (n = 70)
  ------------------------------------ ----------------------------------- ----------------------------------
  Menopausal state                                                         
   Premenopausal                       33 (41.2)                           25 (35.7)
   Postmenopausal                      47 (58.8)                           45 (64.3)
  First degree family history                                              
   Negative                            75 (93.8)                           65 (92.9)
   Positive                            5 (6.2)                             5 (7.1)
  Histological type of breast cancer                                       
   Duct carcinoma                      80 (100)                            30 (42.9)
   Lobular carcinoma                   0 (0.0)                             23 (32.8)
   Mixed duct and lobular              0 (0.0)                             10 (14.3)
   Poorly differentiated tumor         0 (0.0)                             7 (10.0)
  Biological type of breast cancer                                         
   Luminal A                           43 (53.8)                           27 (38.6)
   Luminal B                           3 (3.7)                             7 (10.0)
   Basal-like                          34 (42.5)                           18 (25.7)
   HER2^+^                             0 (0.0)                             18 (25.7)
  Tumor grade                                                              
   GI                                  12 (15.0)                           0 (0)
   GII                                 65 (81.3)                           30 (42.9)
   GIII                                3 (3.7)                             40 (57.1)
  Tumor stage                                                              
   I                                   10 (12.5)                           0 (0.0)
   IIA                                 45 (56.2)                           0 (0.0)
   IIB                                 25 (31.3)                           0 (0.0)
   IIIA                                0 (0.0)                             32 (45.7)
   IIIC                                0 (0.0)                             3 (4.3)
   IV                                  0 (0.0)                             35 (50)
  Lymph node involvement                                                   
   Negative                            55 (68.8)                           
   Positive                            25 (31.2)                           70 (100)
  Estrogen receptors                                                       
   Negative                            33 (41.2)                           36 (51.4)
   Positive                            47 (58.8)                           34 (48.6)
  Progesterone receptors                                                   
   Negative                            35 (43.7)                           35 (50)
   Positive                            45 (56.3)                           35 (50)
  HER 2 expression                                                         
   Score 0                             77 (96.3)                           45 (64.3)
   Score 1                             3 (3.7)                             25 (35.7)
  NPI                                                                      
   Good prognosis                      37 (46.3)                           0 (0.0)
   Moderate prognosis                  43 (53.7)                           27 (38.6)
   Poor prognosis                      0 (0.0)                             43 (61.4)
  IHPI                                                                     
   Good prognosis                      45 (56.3)                           35 (50)
   Moderate prognosis                  35 (43.7)                           17 (24.3)
   Bad prognosis                       0 (0.0)                             18 (25.7)
  Risk of recurrence                                                       
   Intermediate                        72 (90)                             28 (40)
   High                                8 (10)                              42 (60)

Values in parentheses indicate percentage; BC, breast cancer; n, number; HER2, human epidermal growth factor receptor 2; NPI, Nottingham prognostic index; IHPI, immunohistochemical prognostic index.

###### 

Some demographic and laboratory data of study subjects.

  -------------------------------------------------------------------------------------------------------------------
  Parameter                      Controls (n = 150)\   Patients (n = 150)\   *P* value
                                 (mean ± SD)           (mean ± SD)           
  ------------------------------ --------------------- --------------------- ----------------------------------------
  Age (years)                    50.2 ± 4.2            52.1 ± 3.8            0.223

  BMI (kg/m^2^)                  26.3 ± 3.2            27.1 ± 3.5            0.275

  White blood cell (X10^3^/µl)   6.7 ± 1.6             6.5 ± 1.8             0.152

  ALT (U/l)                      29.7 ± 3.1            31.4 ± 2.9            0.417

  AST (U/l)                      27.2 ± 7.1            28.7 ± 6.8            0.599

  Albumin (g/l)                  44.0 ± 5.8            43.9 ± 6.1            0.539

  Serum creatinine (μmol/l)      84.5 ± 11.9           85.3 ± 11.1           0.397

  Blood urea nitrogen (mmol/l)   6.3 ± 2.0             6.8 ± 2.3             0.089

  PT (s)                         10.7 ± 2.4            11.1 ± 2.1            0.104

  APTT (s)                       31.4 ± 4.5            30.1 ± 4.8            0.432

  Fibrinogen (g/l)               2.5 ± 1.2             3.9 ± 1.6             0.000[⁎](#tf0005){ref-type="table-fn"}

  D-Dimer (ng/ml)                151.0 ± 81.1          549.5 ± 101.2         0.007[⁎](#tf0005){ref-type="table-fn"}

  TAFI Ag (%)                    91.1 ± 19.2           101.3 ± 24.4          0.004[⁎](#tf0005){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------

n; number, BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; APTT, activated partial thromboplastin time; TAFI Ag, thrombin-activatable fibrinolysis inhibitor antigen.

*P* \< 0.05.

###### 

Genotype and allele frequencies of TAFI Thr325Ile polymorphism in studied subjects.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TAFI Genotypes                Controls\   BC patients\   Odds ratio\       *P ^a^* value   Early stage BC patients\   Odds ratio\      *P ^a^* value   Late stage BC patients\   Odds ratio (95% CI)   *P ^a^* value
                                (n = 150)   (n = 150)      (95% CI)                          (n = 80)                   (95% CI)                         (n = 70)                                        
  ----------------------------- ----------- -------------- ----------------- --------------- -------------------------- ---------------- --------------- ------------------------- --------------------- ---------------
  Thr/Thr (CC)                  67 (44.7)   42 (28.0)      1(Ref.)                           17 (21.2)                  1(Ref.)                          25 (35.7)                 1(Ref.)               

  Thr/Ile (CT)                  63 (42.0)   75 (50.0)      1.9 (1.1--3.3)    0.01^⁎^         43 (53.8)                  2.7 (1.4--5.2)   0.003^⁎^        32 (45.7)                 1.4 (0.7--2.5)        0.334

  Ile/Ile (TT)                  20 (13.3)   33 (22.0)      2.6 (1.3--5.5)    0.01^⁎^         20 (25.0)                  3.9 (1.7--8.9)   \< 0.001^⁎^     13 (18.6)                 1.7 (0.8--4.0)        0.191

  Thr/Ile (CT) + Ile/Ile (TT)   83 (55.3)   108 (72.0)     2.08 (1.3--3.5)   0.002^⁎^        63 (78.8)                  2.9 (1.6--5.6)   \< 0.001^⁎^     45 (64.3)                 1.5 (0.8--2.6)        0.210

  TAFI alleles                                                                                                                                                                                           

   C                            197 (66)    159 (53)       1.7 (1.2--2.4)    0.001^⁎^        77 (48.1)                  2.1 (1.4--3.0)   \< 0.001^⁎^     82 (58.6)                 1.4 (0.9--2.0)        0.151

   T                            103 (34)    141 (47)       83 (51.9)         58 (41.4)                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The TAFI genotype\'s reference group was CC and the TAFI allele\'s reference group was allele C. TAFI, thrombin-activatable fibrinolysis inhibitor; N, number; Ref., reference; \*Chi-square test is statistically significant at confidence interval (CI) 95%; ^a^ When compared with controls. *P* value was statistically non-significant when early stage BC patients compared to late stage group by the genotype and allele frequencies.

###### 

The relationship between plasma TAFI levels among different *TAFI* genotypes and different clinicopathological parameters of breast cancer patients.

  Patient characteristics                  TAFI level by Thr325Ile genotypes                    
  ---------------------------------------- ----------------------------------- ---------------- -----
  Menopausal state                                                                              
   Premenopausal                           100 (75--126)                       80 (71--126)     58
   Postmenopausal                          130 (86--156)                       84 (70--150)     92
  First degree family history                                                                   
   Negative                                102 (75--156)                       86 (70--150)     140
   Positive                                0                                   79.5 (78--93)    10
  Histological type of Breast cancer\*                                                          
   Duct carcinoma                          102 (86--156)                       79 (70--124)     110
   Lobular carcinoma                       115 (75--156)                       100 (75--175)    23
   Mixed duct and lobular                  94 (86--102)                        120 (86--125)    10
   Poorly differentiated tumor             143 (130--155)                      120 (100--140)   7
  Biological sub-type of Breast cancer\*                                                        
   Luminal A                               100 (75--156)                       79.5 (71--124)   70
   Luminal B                               0                                   89.5 (76--120)   10
   Basal-like                              110 (86--156)                       84 (70--107)     52
   HER2^+^                                 137 (130--145)                      126 (79--150)    18
  Tumor grade                                                                                   
   GI                                      0 (0)                               82 (75--100)     12
   GII                                     101 (75--156)                       80 (70--124)     95
   GIII                                    137 (86--156)                       100 (75--150)    43
  Tumor stage\*                                                                                 
   Early (I, IIA and IIB)                  102 (100--126)                      79 (70--124)     80
   Late (IIIA, IIIC and IV)                115 (75--156)                       95 (71--150)     70
  NPI\*                                                                                         
   Good prognosis                          105 (101--110)                      80 (70--100)     37
   Moderate prognosis                      100 (75--156)                       79 (70--124)     70
   Poor prognosis                          137 (86--156)                       100 (75--150)    43
  IHPI\*                                                                                        
   Good prognosis                          100 (75--156)                       80 (71--124)     80
   Moderate prognosis                      110 (86--156)                       84 (70--107)     52
   Bad prognosis                           138 (130--145)                      126 (79--150)    18
  Risk of recurrence\*\*                                                                        
   Intermediate                            130 (100--126)                      100 (79--150)    100
   High                                    115 (75--156)                       79 (70--124)     50

TAFI (thrombin-activatable fibrinolysis inhibitor) Ag levels were expressed as percentage of normal pooled plasma (NPP); data are presented as median (range); HER2, human epidermal growth factor receptor 2; NPI, Nottingham Prognostic Index; IHPI, Immunohistochemical Prognostic Index. Comparisons were performed by Kruskal--Wallis test followed by Tukey multiple comparison test for each group in case of more than two subgroup analysis. \*, indicates a statistically significant difference P \< 0.05. \*\*, indicates statistically significantly difference *P* \< 0.001.
